权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness Decisions

护理点 RT-PCR 系统可为 COVID-19 和呼吸道疾病决策提供信息

基本信息

批准号：
10688237
负责人：
Frederick R Haselton
金额：
$ 77.42万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-18 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10688237
关键词：
2019-nCoV Academic Medical Centers Bacteria Bacterial Infections Biochemical Biomedical Engineering CLIA certified COVID-19 COVID-19 assay COVID-19 detection COVID-19 diagnostic COVID-19 pandemic COVID-19 testing Characteristics Clinic Clinical Collaborations Containment DNA Data Device Designs Devices Diagnosis Diagnostic Engineering Environment Epidemiology Goals Health Human Image Infection Infection prevention Infectious Diseases Research Influenza Laboratories Light Methodology Methods Molecular Molecular Diagnosis Monitor Nucleic Acids Optics Patients Performance Physicians Physicians&apos Offices Population Preparation Public Health RNA RNA Viruses RNase P Reaction Reagent Reporting Resource-limited setting Resources Respiratory Tract Infections Reverse Transcriptase Polymerase Chain Reaction Sampling Sensitivity and Specificity Specificity Specimen Supportive care Symptoms System Technology Temperature Tennessee Testing Time Training Tube Viral Virus Work amplification detection clinically relevant cost cost effective design detection method diagnostic assay enantiomer experience follow-up instrument instrumentation molecular diagnostics multiplex assay nasopharyngeal swab novel pathogen point of care point-of-care diagnostics preclinical evaluation primary care setting research clinical testing respiratory respiratory pathogen technology validation tool urgent care

项目摘要

Project Summary The ongoing COVID-19/SARS-CoV-2 pandemic highlights the need for simple, rapid, and cost-effective testing for respiratory infections at the point-of-care, including physician’s offices, urgent-care settings, ambulatory procedural centers, and low-resource environments. The need is particularly notable for respiratory infections, such as COVID-19 and influenza, which can present with similar symptoms yet require distinct management strategies. With its high sensitivity and specificity, RT-PCR is the gold standard for the molecular diagnosis and differentiation among respiratory pathogens. Traditional RT-PCR workflow requires significant control over specimen contents and reaction conditions, with current methods requiring nucleic acid extraction prior to amplification and detection. The net result is increased complexity, cost, and/or turnaround time for diagnosis. In this context, we have observed in recent influenza studies that outstanding analytic performance characteristics can be achieved without RNA extraction, by applying our novel workflow and Adaptive PCR technology. Unlike traditional RT-PCR, Adaptive RT-PCR incorporates mirror-image L-DNA enantiomers— identical in sequence to PCR primers and targets—that modify cycling conditions to match the biochemical sample contents, thus eliminating the need to monitor reaction temperature. The direct monitoring of reaction conditions overcomes many of the limitations of traditional PCR, facilitating direct amplification within the original specimen matrix, simplifying instrument design, and enabling single-tube analyses. SARS-CoV-2 and influenza are both enveloped RNA viruses, with specimens collected in the same manner (i.e. nasopharyngeal swab) and using the same viral transport medium. Therefore, we hypothesize that we may eliminate RNA extraction for this virus, like we have done for influenza, by performing Adaptive RT-PCR directly on clinical specimens. We propose to enable a simplified methodology through Adaptive RT-PCR, creating diagnostics for COVID-19 and other respiratory pathogens without RNA extraction. As a collaboration between biomedical engineers and a COVID-19 diagnostic laboratory, we seek to develop a workflow and instrument that are simple-to-use, cost-effective, and suitable for point-of-care settings, tools that can rapidly inform treatment and management strategies. To achieve this goal, Aim 1 will evaluate the performance of RT- PCR directly – that is, without RNA extraction – using both traditional and Adaptive RT-PCR instrumentation. Aim 2 will develop multiplexed amplification reagents to create a sensitive and specific respiratory panel that detects SARS-CoV-2, four other viruses, two bacteria, and one control target. Ultimately, Aim 3 will design and fabricate a self-contained Adaptive RT-PCR instrument suitable for point-of-care settings, while validating this system using characterized human specimens in a CLIA-accredited lab environment. Completion of this project will result in a novel point-of-care tool for both the established and emerging respiratory infections that threaten public health, facilitating rapid treatment, follow-up, infection prevention, and epidemiologic containment.

项目摘要正在进行的新冠肺炎/SARS-CoV-2大流行突出表明，需要简单、快速和具有成本效益的在护理地点进行呼吸道感染检测，包括医生办公室、紧急护理环境、流动的程序中心和低资源环境。对于呼吸道来说，这种需求尤其值得注意新冠肺炎和流感等感染，它们可以出现类似的症状，但需要不同的管理策略。RT-pcr以其高度的敏感性和特异性成为检测分子水平的金标准。呼吸道病原体的诊断和鉴别。传统的RT-PCR工作流程需要大量对样本含量和反应条件的控制，目前的方法需要提取核酸在扩增和检测之前。最终结果是增加了复杂性、成本和/或周转时间诊断。在这方面，我们在最近流感研究中观察到，出色的分析表现通过应用我们的新工作流程和自适应PCR，可以在不提取RNA的情况下获得特征技术与传统的逆转录聚合酶链式反应不同，适应性逆转录聚合酶链合成了镜像的L-脱氧核糖核酸对映体- 在序列上与PCR引物和靶标相同-修改循环条件以匹配生化样品含量，从而消除了监控反应温度的需要。对反应的直接监控这些条件克服了传统聚合酶链式反应的许多局限性，便于在原始基因中直接扩增。样品矩阵，简化了仪器设计，实现了单管分析。 SARS-CoV-2和流感都是有包膜的RNA病毒，样本收集在同一方法(即鼻咽拭子)和使用相同的病毒传输介质。因此，我们假设我们可以通过执行适应性RT-PCR来消除这种病毒的RNA提取，就像我们对流感所做的那样直接在临床标本上。我们建议通过自适应RT-PCR实现简化的方法，无需提取核糖核酸即可诊断新冠肺炎和其他呼吸道病原体。作为协作在生物医学工程师和新冠肺炎诊断实验室之间，我们寻求开发一种工作流程和简单易用、经济实惠且适用于护理点设置的工具，这些工具可以快速告知治疗和管理策略。为了实现这一目标，目标1将评估RT- 使用传统和自适应RT-PCR仪器直接--也就是不提取RNA--进行聚合酶链式反应。 AIM 2将开发多重扩增试剂，以创建敏感和特异的呼吸面板检测SARS-CoV-2、其他四种病毒、两种细菌和一个控制目标。最终，Aim 3将设计和制作一种适用于护理点设置的自包含自适应RT-PCR仪器，同时验证这一点在CLIA认可的实验室环境中使用特性化的人体样本的系统。本项目竣工将为已有的和新出现的呼吸道感染带来一种新的护理点工具，这些感染威胁到公共卫生，促进快速治疗、后续行动、感染预防和流行病控制。

项目成果

期刊论文数量（5）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Forty Years of Molecular Diagnostics for Infectious Diseases.

DOI：
10.1128/jcm.02446-21
发表时间：
2022-10-19
期刊：
Journal of clinical microbiology
影响因子：
9.4
作者：
通讯作者：

Ligation-based assay for variant typing without sequencing: Application to SARS-CoV-2 variants of concern.

DOI：
10.1111/irv.13083
发表时间：
2023-01
期刊：
INFLUENZA AND OTHER RESPIRATORY VIRUSES
影响因子：
4.4
作者：
Nelson, Dalton J.;Shilts, Meghan H.;Pakala, Suman B.;Das, Suman R.;Schmitz, Jonathan E.;Haselton, Frederick R.
通讯作者：
Haselton, Frederick R.

A safer framework to evaluate characterization technologies of exhaled biologic materials using electrospun nanofibers.

使用电纺纳米纤维评估呼出生物材料表征技术的更安全框架。